Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis.

Brain metastases from prostate cancer: an 11-year analysis in the MRI era with emphasis on imaging characteristics, incidence, and prognosis.
复制标题

DOI:
10.1111/j.1552-6569.2012.00767.x
复制
发表时间:
2014-03
期刊:
Journal of neuroimaging : official journal of the American Society of Neuroimaging
影响因子:
--
通讯作者:
Young RJ
Young RJ
中科院分区:
其他
文献类型:
--
作者:
Hatzoglou V;Patel GV;Morris MJ;Curtis K;Zhang Z;Shi W;Huse J;Rosenblum M;Holodny AI;Young RJ

文献摘要

被引文献

相似文献

前列腺癌脑转移并不常见,其影像学表现尚未明确。本研究的主要目的是评估起源于前列腺癌的脑实质转移的发病率、MRI特征和预后。我们回顾性地确定了2000年至2010年间21例前列腺癌患者和脑转移的证据。我们回顾了最初的脑部MRI扫描,并根据MRI上的位置和外观来描述病变,同时也确定了患者的人口统计学、分期和生存率。前列腺癌脑转移的发生率为0.16%。在发现脑转移时,95%的患者并发骨转移,86%的患者并发淋巴结转移,76%的患者并发肝和/或肺转移。71%的患者脑转移为多灶性,33%为出血性,19%为扩散受限,19%为部分囊性/坏死。发现脑转移后的中位总生存期为2.8个月。前列腺癌脑转移仍然是一种罕见的现象,最常发生在广泛播散的骨和软组织疾病的设置。非腺癌患者更容易发生脑转移。MRI表现多变,预后差。
Brain metastases from prostate cancer are uncommon and their imaging appearance has not been well defined. The main objectives of this study were to evaluate the incidence, MRI characteristics, and prognosis of parenchymal brain metastases originating in prostate cancer. We retrospectively identified 21 patients with prostate cancer and evidence of brain metastases from 2000 to 2010. We reviewed the initial brain MRI scans and characterized the lesions according to location and appearance on MRI, while also determining patient demography, staging, and survival. The incidence of brain metastasis from prostate cancer was .16%. At the time of brain metastasis detection, 95% of the patients had concurrent osseous metastases, 86% lymph node metastases, and 76% liver and/or lung metastases. Brain metastases were multifocal in 71% of patients, hemorrhagic in 33%, diffusion restricted in 19%, and partially cystic/necrotic in 19%. The median overall survival after brain metastasis detection was 2.8 months. Brain metastasis from prostate cancer remains a rare phenomenon that most frequently occurs in the setting of widely disseminated bone and soft tissue disease. Patients with nonadenocarcinoma pathology are more likely to develop brain metastases. The MRI appearance is highly variable and prognosis is poor.